Time & Date: 2 September, 15:15 – 16:15 CEST
Chairpersons: A. Khanani USA & U. Chakravarthy UK
Speakers & Presentations:
U. Chakravarthy UK
15:15 Welcome
M.A. Zouache USA
15:17 Protective CFH-CFHR5 haplotypes mitigate risk for age-related macular degeneration associated with the ARMS2/HTRA1 locus.
F. G. Holz GERMANY
15:23 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
M.S. Figueroa SPAIN
15:29 Key Clinical Pearls for Evaluating Surgical Candidates, and Patient Preference, for the Port Delivery System With Ranibizumab
U. Chakravarthy UK
15:35 Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the Port Delivery System With Ranibizumab (PDS)
A. Khanani USA
15:41 Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab
G. Boscia ITALY
15:47 Macular thickness and visual acuity are characterized by a quadratic nonlinear relation in previously treated neovascular AMD eyes: retinal thickness deviation values may better predict visual function in these eyes
M. Airaldi ITALY
15:53 Differences in long-term progression of atrophy between neovascular and non-neovascular age-related macular degeneration
V. Sarao ITALY
15:59 Progression of geographic atrophy in the course of treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor agents
M.L. Martínez Sánchez SPAIN
16:05 COVID-19, the pandemic that held Europe to a standstill and its impact in patients affected by neovascular age related macular degeneration (nAMD). The nAMD EUROCOVCAT study.
All Faculty
16:11 Discussion
